Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2005
11/23/2005CN1700917A Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
11/23/2005CN1700916A Use of HIV-protease inhibitors to block cell migration and/or invasion, tissue inflitration and oedema formation
11/23/2005CN1698896A Method for preparing compound beta lactam sodium salt/sodium benemid for injection
11/23/2005CN1698895A Oral administered compound colloid pectin bismuth preparation and its preparing process
11/23/2005CN1698894A Tumor necrosis factor antagonists and their use in endometriosis
11/23/2005CN1698603A Pharmaceutical composition
11/23/2005CN1698601A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
11/23/2005CN1228145C Device and method for coating high-efficient ingredient on plants, application thereof and finished product
11/23/2005CN1228087C Medicinal preparation and its prepn. and application
11/23/2005CN1228041C Methods for preparation of lipid-encapsulated therapeutic agents
11/23/2005CN1228039C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
11/22/2005US6967245 Ucp5
11/22/2005US6967206 Compositions and methods for increasing growth hormone levels
11/22/2005US6967204 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
11/22/2005US6967203 Use of pyridoindolone derivatives for preparing anticancer medicines
11/22/2005US6967199 Substituted diamine derivatives useful as motilin antagonists
11/22/2005US6967100 Propagating islet of langerhans cells; obtain cells, culture in presence of bone morphogenic protein or modulator, monitor proliferation of cells
11/22/2005US6967094 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
11/22/2005US6967030 Formulation for insulin and glucose control
11/22/2005US6967025 A disposable product comprising an absorbent core containing atleast a spore which has the ability to germinate into a microorganism which is antagonist of undesirable strains of microorgansims
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005US6967022 Ganglioside-KLH conjugate vaccines plus QS-21
11/22/2005CA2277100C Cyclic sulfone derivatives
11/22/2005CA2249336C Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
11/17/2005WO2005108574A1 Gm1 PROMOTER AND USE THEREOF
11/17/2005WO2005108370A1 Benzene compounds
11/17/2005WO2005107810A2 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
11/17/2005WO2005107809A2 Antimycobacterial pharmaceutical composition comprising an antitubercular drug
11/17/2005WO2005107808A2 Combination of atypical antipsychotics and 5-ht1b receptor antagonists
11/17/2005WO2005107807A2 Cerebral intraventricular transplantation as method of treating amyotrophic lateral sclerosis
11/17/2005WO2005107806A1 Compositions for affecting weight loss
11/17/2005WO2005107805A1 Aβ-PRODUCTION INHIBITOR
11/17/2005WO2005107804A1 Therapeutic agent for respiratory ailment
11/17/2005WO2005107783A1 Food containing extract from bark of pine
11/17/2005WO2005107782A2 Use of a modulator of gene expression in the treatment of cancer
11/17/2005WO2005107778A1 Body fat reducing preparation
11/17/2005WO2005107774A1 Pharmaceutical wound healing composition
11/17/2005WO2005107741A1 Novel oral compositions comprising antitubercular drugs in combination with alpha-tocopherol
11/17/2005WO2005107740A1 Enhancing the efficacy of tubercular drugs by combination with alpha tocopherol
11/17/2005WO2005107737A1 Antifatigue composition
11/17/2005WO2005107733A1 Dermatological external preparation for local anesthesia
11/17/2005WO2005107731A1 Remedies containing vitamin k2 as the active ingredient
11/17/2005WO2005107727A1 Steroid intraocular implants having an extended sustained release for a period of greater than two months
11/17/2005WO2005107726A2 Method for the treatment of back pain
11/17/2005WO2005107717A2 Oral dosage form for the extended release of biguanide and sulfonylurea
11/17/2005WO2005107470A2 Use of carbonic anhydrase inhibitors for insect control and malaria treatment
11/17/2005WO2005084654A3 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
11/17/2005WO2005070427A8 Compounds for the sustained reduction of body weight
11/17/2005WO2005065696A8 Pharmaceutical compositions comprising an extract of euphorbia prostrata
11/17/2005WO2005020972A3 Combination therapy for the treatment of ocular neovascular disorders
11/17/2005WO2005016270A3 Methods for treatment of dermatological conditions
11/17/2005WO2003042399A8 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/17/2005US20050256198 2-[(4-{3-[benzyl(hexyl)amino]-3-oxopropyl}phenoxy)methyl]benzoic acid;peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations
11/17/2005US20050256187 Method and composition for synergistic topical therapy for neuromuscular pains
11/17/2005US20050256183 Hsp90-inhibiting zearalanol compounds and methods of producing and using same
11/17/2005US20050256175 Novel glucagon antagonists/inverse agonists
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256141 Remedies for glomerular diseases
11/17/2005US20050256128 N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide; tuberculosis including multi-drug resistant and/or latent tuberculosis; antitubercular drugs
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256112 Enhancing the serotonergic neurotransmission; side effects reduction; nervous system disorders; sexual disorders; analgesics; antidepressants; anticancer; anxiolytic agents; neurodegenerative diseases; gastrointestinal tract disorders; eating disorders
11/17/2005US20050256093 Branched polyamine steroid derivatives
11/17/2005US20050256086 Fosinopril formulation
11/17/2005US20050256070 Adjuvant
11/17/2005US20050256066 Fredericamycin derivatives
11/17/2005US20050256059 administering D-mannose for producing neurosalutary effect in a patient useful in treatment of neurological disorders, including retinal and optic nerve damage
11/17/2005US20050256055 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
11/17/2005US20050256053 Combined use of a GLP-1 compound and another drug for treating dyslipidemia
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050256033 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/17/2005US20050255576 PGDS inhibitor; antiallergies, sleep control, antiobesity and brain wound healing; Crystals of a complex of human origin hematopoietic prostaglandin D synthase, glutathione and a substrate analog or an inhibitor
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255518 Methods and compositions for the treatment and diagnosis of pain disorders using 46566
11/17/2005US20050255178 Enhancing the effectiveness of an inhaled therapeutic gas
11/17/2005US20050255163 Co-grinding process for the preparation of a ternary composition
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255151 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
11/17/2005US20050255124 HCV E1E2 vaccine compositions
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005US20050255100 Isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5; tumor necrosis factor blocking agent; cyclosporine immunosuppressant; antibiotic; anti-inflammatory; graft versus host disease, viral infection, cancer, leukemia, immunodeficiency, autoimmune disorder
11/17/2005US20050255096 Combination treatment for acute myocardial infarction
11/17/2005US20050255092 an isolated microorganism of the genus Bacillus that is capable of inhibiting escherichia coli disease and improving performance of an animal (pigs); antidiarrhea andantiedemic agents
11/17/2005US20050255091 Hydrogels for biomedical applications
11/17/2005US20050255071 Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
11/17/2005US20050255059 Personal care compositions and methods regulating mammalian hair growth
11/17/2005CA2774146A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months
11/17/2005CA2566699A1 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
11/17/2005CA2566083A1 Antifatigue composition
11/17/2005CA2565996A1 Combination of atypical antipsychotics and 5-ht1b receptor antagonists
11/17/2005CA2565295A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months
11/17/2005CA2564394A1 Method for the treatment of back pain
11/17/2005CA2560264A1 Gm1 promoter and use thereof
11/16/2005EP1595936A1 Antioxidative composition and composition for external use
11/16/2005EP1595544A1 Remedy for diabetes
11/16/2005EP1595543A2 Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil
11/16/2005EP1595540A1 Composition containing an angiotensin II receptor antagonist and a diuretic and its use for the treatment of hypertension
11/16/2005EP1595539A1 Drug for reducing side effects in ribavirin interferon combination therapy
11/16/2005EP1595129A2 Methods of identifying modulators of cellular glycosylation using gtrap3-18
11/16/2005EP1594528A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins
1 ... 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 ... 1151